H.C. Wainwright analyst Swayampakula Ramakanth raised the firm’s price target on Celcuity (CELC) to $77 from $66 and keeps a Buy rating on the shares following the gedatolisib data. The firm increased the probability of launch to 90% from 80%.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CELC: